New York-based Nasdaq, Inc. (NDAQ) operates as a technology company that serves capital markets and other industries ...

However, 121 U.S. companies went public through the third quarter of 2024, which was more than the 101 IPOs during the same ...

Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...

Smithfield Foods on Monday made public its paperwork for its New York initial public offering as the maker of Farmland bacon ...

Shares of this specialty technology company have gained 141% over the past year, and that could be just the beginning.

Simpson Thacher partners offer IPO tips for private companies, noting that having an independent board and the correct ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

Drug developer Maze Therapeutics Inc.'s rollercoaster ride is leading to the Bay Area's first biotech IPO filing of 2025.

Next year could also mark a turning point for fintech IPOs after several challenging years. Affirm’s (AFRM) “Buy Now, Pay Later” rival Klarna is expected to go public next year. In its last ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor ...

Palo Alto Networks (PANW -1.22%) may be recognized in the marketplace as a leader in cybersecurity solutions, but investors ...

Ascentage Pharma Group International (HK:6855) has released an update. Ascentage Pharma Group International has filed a ...